Physicochemical Properties
| Molecular Formula | C24H42N2O4 |
| Molecular Weight | 422.60 |
| CAS # | 2878481-07-1 |
| Appearance | Typically exists as solids at room temperature |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | CARM1 9 nM (IC50); PRMT1 56 nM (IC50); PRMT6 30 nM (IC50); PRMT8 31 nM (IC50); PRMT3 2637 nM (IC50); PRMT5 >100,000 nM (IC50) |
| ln Vitro | CARM1-IN-4 (compound 11f) exhibited significant antiproliferative activity in HCT116 cell line (IC50=3.13 μM)[1]. CARM1-IN-4 (0.625-5 μM; 72 hours) induced dose-dependent apoptosis in HCT116 cells[1]. CARM1-IN-4 (0.625-10 μM; 48 hours) effectively inhibited the methyltransferase activity of CARM1 and affected the asymmetric demethylation level of CARM1 substrates in the cellular environment[1]. CARM1-IN-4 exhibited relatively high mitochondrial stability and a long half-life in mouse mitochondria (T1/2=217 minutes)[1]. |
| ln Vivo | CARM1-IN-4 (compound 11f; 10, 25 mg/kg/day; intraperitoneal injection; for 12 days) showed significant tumor inhibitory effects on BALB/c nude mice bearing subcutaneous HCT116 xenografts [1]. |
| Cell Assay |
Apoptosis Analysis[1] Cell Types: HCT116 cells Tested Tested Concentrations: 0.625, 1.25, 2.5, 5 μM Incubation Duration: 72 h Experimental Results: Illustrated a noticeable increase in the overall percentages of both early and late apoptotic cells. Western Blot Analysis[1] Cell Types: HCT116 cells Tested Tested Concentrations: 0.625, 1.25, 2.5, 5, 10 μM Incubation Duration: 48 h Experimental Results: Caused dose-dependent reductions in global asymmetric dimethylarginine (aDMA) and asymmetric dimethyl-PABP1 levels in HCT116 cells. |
| Animal Protocol |
Animal/Disease Models: 6 to 8-week-old female BALB/c nude mice bearing subcutaneous HCT116 xenograft[1] Doses: 10, 25 mg/kg Route of Administration: Intraperitoneal injection; daily; for 12 days Experimental Results: Showed evident inhibitory effect. |
| References |
[1]. Structure-based discovery of potent CARM1 inhibitors for colorectal cancer therapy. Eur J Med Chem. 2024 Mar 4:269:116288. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3663 mL | 11.8315 mL | 23.6630 mL | |
| 5 mM | 0.4733 mL | 2.3663 mL | 4.7326 mL | |
| 10 mM | 0.2366 mL | 1.1832 mL | 2.3663 mL |